<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objectives of this study were to expand on recent observations that have suggested decreased thrombopoietin receptor (c-Mpl) expression in megakaryocytes of patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) and agnogenic <z:mpath ids='MPATH_173'>myeloid metaplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMM</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We applied an immunoperoxidase method with anti-c-Mpl antibody to 55 bone marrow sections from previously untreated patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>These included 8 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, 15 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMM</z:e>, 9 with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, 5 with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 9 with the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e> and 9 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The findings were compared with those in four patients with reactive <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> (RE), six with immune thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>) and five <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="4" pm="."><plain>Staining intensity (SI) was moderate to strong both in <z:mpath ids='MPATH_458'>normal</z:mpath> controls and in patients with RE or <z:chebi fb="0" ids="16039">ITP</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, SI was weak in variable proportions of the megakaryocytes in every one of the aforementioned clonal myeloid disorders </plain></SENT>
<SENT sid="6" pm="."><plain>The staining pattern (SP) was relatively uniform in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Neither SI nor SP was significantly correlated with certain clinical or laboratory parameters </plain></SENT>
<SENT sid="8" pm="."><plain>We concluded that altered megakaryocyte c-Mpl expression may be a nonspecific phenomenon in various subtypes of both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>However, the characteristic staining patterns may complement the morphological distinction between clonal and reactive myeloproliferation </plain></SENT>
</text></document>